FN2 Earnings Intelligence
Axsome Therapeutics, Inc. income statement (quarterly)
Axsome Therapeutics, Inc. (AXSM) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $327.3 | $300.9 | $303 | $325.3 | $305.1 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $104.8 | $121.5 | $150 | $171 | $191.2 | $221.1 | $249.2 |
| % Growth | - | - | - | - | - | 47.4% | 45.7% |
| Gross Profit | $99.8 | - | - | - | - | - | - |
| % Margin | 95.2% | - | - | - | - | - | - |
| EBITDA | - | -$56.8 | - | - | -$63.2 | - | - |
| % Margin | - | -46.8% | - | - | -33.1% | - | - |
| Net Income | -$64.6 | -$59.4 | -$48 | -$47.2 | -$64.5 | - | - |
| % Margin | -61.7% | -48.9% | -32.0% | -27.6% | -33.8% | - | - |
| Diluted EPS | -$1.34 | -$1.22 | -$0.97 | -$0.94 | -$1.26 | -$0.89 | -$0.63 |
| % Growth | - | - | - | - | - | 8.0% | 32.5% |
| Operating Cash Flow | - | -$43.4 | - | - | -$20.7 | - | - |
| CapEx | - | $0.3 | - | - | $0.1 | - | - |
| Free Cash Flow | - | -$43.7 | - | - | -$20.8 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $104.8 | $121.5 | $150 | $171 | $191.2 | $221.1 | $249.2 |
| Gross Profit | $99.8 | - | - | - | - | - | - |
| EBITDA | - | -$56.8 | - | - | -$63.2 | - | - |
| Net Income | -$64.6 | -$59.4 | -$48 | -$47.2 | -$64.5 | - | - |
| Diluted EPS | -$1.34 | -$1.22 | -$0.97 | -$0.94 | -$1.26 | -$0.89 | -$0.63 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $327.3 | $300.9 | $303 | $325.3 | $305.1 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $180 | $181.4 | $117.5 | $117.6 | $117.8 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -$43.4 | - | - | -$20.7 |
| Capital Expenditure | - | $0.3 | - | - | $0.1 |
| Free Cash Flow | - | -$43.7 | - | - | -$20.8 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 95.2% | - | - | - | - |
| EBITDA Margin | - | -46.8% | - | - | -33.1% |
| Net Margin | -61.7% | -48.9% | -32.0% | -27.6% | -33.8% |
| FCF Margin | - | -36.0% | - | - | -10.9% |
| Diluted EPS Growth | - | - | - | - | - |
Get the AXSM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.